Literature DB >> 16621987

Conversion of alloantigen-specific CD8+ T cell anergy to CD8+ T cell priming through in vivo ligation of glucocorticoid-induced TNF receptor.

Juyang Kim1, Woon S Choi, Hyun Kang, Hye J Kim, Jae-Hee Suh, Shimon Sakaguchi, Byungsuk Kwon.   

Abstract

In this study, we investigated the effect of an agonistic mAb (DTA-1) against glucocorticoid-induced TNF receptor (GITR) in a murine model of systemic lupus erythematosus-like chronic graft-vs-host disease (cGVHD). A single dose of DTA-1 inhibited the production of anti-DNA IgG1 autoantibody and the development of glomerulonephritis, typical symptoms of cGVHD. DTA-1-treated mice showed clinical and pathological signs of acute GVHD (aGVHD), such as lymphopenia, loss of body weight, increase of donor cell engraftment, and intestinal damage, indicating that DTA-1 shifted cGVHD toward aGVHD. The conversion of cGVHD to aGVHD occurred because DTA-1 prevented donor CD8+ T cell anergy. Functionally active donor CD8+ T cells produced high levels of IFN-gamma and had an elevated CTL activity against host Ags. In in vitro MLR, anergic responder CD8+ T cells were generated, and DTA-1 stimulated the activation of these anergic CD8+ T cells. We further confirmed in vivo that donor CD8+ T cells, but not donor CD4+ T cells, were responsible for the DTA-1-mediated conversion of cGVHD to aGVHD. These results indicate that donor CD8+ T cell anergy is a restriction factor in the development of aGVHD and that in vivo ligation of GITR prevents CD8+ T cell anergy by activating donor CD8+ T cells that otherwise become anergic. In sum, our data suggest GITR as an important costimulatory molecule regulating cGVHD vs aGVHD and as a target for therapeutic intervention in a variety of related diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621987     DOI: 10.4049/jimmunol.176.9.5223

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Advances in lupus stemming from the parent-into-F1 model.

Authors:  Charles S Via
Journal:  Trends Immunol       Date:  2010-03-31       Impact factor: 16.687

2.  Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.

Authors:  Scott K Pruitt; David Boczkowski; Nicole de Rosa; N Rebecca Haley; Michael A Morse; Douglas S Tyler; Jens Dannull; Smita Nair
Journal:  Eur J Immunol       Date:  2011-10-26       Impact factor: 5.532

Review 3.  Intervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease.

Authors:  Byungsuk Kwon
Journal:  Exp Mol Med       Date:  2010-10-31       Impact factor: 8.718

Review 4.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

5.  Roles of Host Nonhematopoietic Cells in Autoimmunity and Donor Cell Engraftment in Graft-versus-host Disease.

Authors:  Juyang Kim; Sohye Park; Hyun-A Kim; Daehee Jung; Hyun Ju Kim; Hye-Jeong Choi; Hong Rae Cho; Byungsuk Kwon
Journal:  Immune Netw       Date:  2010-04-30       Impact factor: 6.303

6.  GITRL is associated with increased autoantibody production in patients with rheumatoid arthritis.

Authors:  Linbo Li; Wen Wen; Rulin Jia; Yuhui Li; Xu Liu; Xiaolin Sun; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2016-04-21       Impact factor: 2.980

Review 7.  Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation.

Authors:  Theresa Placke; Hans-Georg Kopp; Helmut Rainer Salih
Journal:  Clin Dev Immunol       Date:  2010-09-26

Review 8.  CD8+ T cells: GITR matters.

Authors:  Simona Ronchetti; Giuseppe Nocentini; Maria Grazia Petrillo; Carlo Riccardi
Journal:  ScientificWorldJournal       Date:  2012-04-30

9.  Enhanced CD8 T cell responses through GITR-mediated costimulation resolve chronic viral infection.

Authors:  Maria Fernanda Pascutti; Sulima Geerman; Edith Slot; Klaas P J M van Gisbergen; Louis Boon; Ramon Arens; Rene A W van Lier; Monika C Wolkers; Martijn A Nolte
Journal:  PLoS Pathog       Date:  2015-03-04       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.